Tom Anchordoquy
-
Professor of Pharmaceutical Sciences,
University of Colorado Anschutz Medical Campus
I joined the faculty at the CU School of Pharmacy in 1998, and my early work focused on the stability of lipid-DNA complexes during freezing and drying. In attempting to assess“recovery” of these new pharmaceutical entities, I became interested in the mechanism by which they facilitated delivery to target cells. In over a decade of work, we eventually realized that these particles were being avidly taken up by circulating immune cells that elicited a potent cytokine response upon intravenous injection. In addition to our work attempting to exploit exosomes for drug delivery, our current projects investigate strategies that harness the nanoparticle-induced immune response to limit off-target accumulation of nanomedicines and promote tumor regression. In addition to these projects, my lab is constantly involved in multiple formulation studies that utilize small molecules to treat a variety of diseases.
Experience-
–present
Professor of Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus


Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research

- Chicago Clearing Corporation And Taxtec Announce Strategic Partnership
- Everstake Expands Institutional Solana Services With Shredstream, Swqos, And Validator-As-A-Service
- Japan Smart Cities Market Size Is Expected To Reach USD 286.6 Billion By 2033 CAGR: 14.6%
- Alchemy Markets Launches Tradingview Integration For Direct Chart-Based Trading
- Blackrock Becomes The Second-Largest Shareholder Of Freedom Holding Corp.
- Pluscapital Advisor Empowers Traders To Master Global Markets Around The Clock
Comments
No comment